Bluebird Bio Inc. (BLUE) Rating Reiterated by SunTrust Banks Inc.
Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating reaffirmed by investment analysts at SunTrust Banks Inc. in a research report issued to clients and investors on Friday.
Other analysts also recently issued research reports about the stock. Jefferies Group reissued a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a research report on Friday, September 23rd. Zacks Investment Research downgraded shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. Maxim Group set a $85.00 price target on shares of Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Cowen and Company reissued an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Finally, Vetr downgraded shares of Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 price target for the company. in a research report on Monday, July 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $90.25.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 65.24 on Friday. The company has a 50-day moving average of $63.52 and a 200 day moving average of $50.81. The stock’s market cap is $2.42 billion. Bluebird Bio has a 52-week low of $35.37 and a 52-week high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The firm earned $1.55 million during the quarter, compared to analyst estimates of $2.01 million. During the same period last year, the business earned ($1.57) EPS. The firm’s revenue was down 68.6% compared to the same quarter last year. Equities research analysts forecast that Bluebird Bio will post ($6.19) EPS for the current fiscal year.
In other Bluebird Bio news, insider Eric Sullivan sold 2,912 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total transaction of $160,189.12. Following the transaction, the insider now owns 4,456 shares in the company, valued at approximately $245,124.56. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 3.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP bought a new position in Bluebird Bio during the first quarter worth approximately $51,095,000. BlackRock Fund Advisors raised its position in Bluebird Bio by 80.0% in the second quarter. BlackRock Fund Advisors now owns 1,386,229 shares of the company’s stock worth $60,010,000 after buying an additional 616,095 shares during the period. State Street Corp raised its position in Bluebird Bio by 41.4% in the second quarter. State Street Corp now owns 1,699,977 shares of the company’s stock worth $73,592,000 after buying an additional 498,041 shares during the period. RTW Investments LLC raised its position in Bluebird Bio by 170.4% in the second quarter. RTW Investments LLC now owns 612,025 shares of the company’s stock worth $26,495,000 after buying an additional 385,654 shares during the period. Finally, Deerfield Management Co. bought a new position in Bluebird Bio during the second quarter worth approximately $14,636,000.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.